Details of the Drug

General Information of Drug (ID: DM5URA2)

Drug Name

Chlorpheniramine

Synonyms

Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1], [2]

Therapeutic Class

Antiallergic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

274.79

Topological Polar Surface Area (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg [4]
Elimination: 10% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 22 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.48399 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.7% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.3 L/kg [4]

Chemical Identifiers

Formula: C16H19ClN2
IUPAC Name: 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
Canonical SMILES: CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
InChI: InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
InChIKey: SOYKEARSMXGVTM-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2725
ChEBI ID: CHEBI:52010
CAS Number: 113-92-8
DrugBank ID: DB01114
TTD ID: D0B7NG
VARIDT ID: DR00595
INTEDE ID: DR0304
ACDINA ID: D00123

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[6], [7], [8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergic rhinitis

ICD Disease Classification

CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
Multidrug resistance-associated protein 1 (ABCC1)	DTP	MRP1	3.67E-01	-1.78E-01	-9.02E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.57E-01	9.43E-03	1.29E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Chlorpheniramine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[59]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[60]
-----------

Coadministration of a Drug Treating the Disease Different from Chlorpheniramine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[59]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[60]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Cariprazine.	Bipolar disorder [6A60]	[60]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Chlorpheniramine when combined with Acetylcholine.	Cataract [9B10]	[61]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[62]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[62]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[62]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Chlorpheniramine and Isocarboxazid.	Depression [6A70-6A7Z]	[63]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and OPC-34712.	Depression [6A70-6A7Z]	[60]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Clomipramine.	Depression [6A70-6A7Z]	[60]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Doxepin.	Depression [6A70-6A7Z]	[59]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Chlorpheniramine and Esketamine.	Depression [6A70-6A7Z]	[64]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Mepenzolate.	Digestive system disease [DE2Z]	[60]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Solifenacin.	Functional bladder disorder [GC50]	[60]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Chlorpheniramine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[65]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Chlorpheniramine and Procarbazine.	Hodgkin lymphoma [2B30]	[63]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Chlorpheniramine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Chlorpheniramine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[67]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Chlorpheniramine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[68]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and ITI-007.	Insomnia [7A00-7A0Z]	[60]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Chlorpheniramine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[69]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Chlorpheniramine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[70]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Chlorpheniramine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[71]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Chlorpheniramine and Lasmiditan.	Migraine [8A80]	[72]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Chlorpheniramine and Flibanserin.	Mood disorder [6A60-6E23]	[73]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Chlorpheniramine caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[74]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Chlorpheniramine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[75]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Chlorpheniramine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[76]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Chlorpheniramine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[77]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Cyclizine.	Nausea/vomiting [MD90]	[60]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Chlorpheniramine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[78]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Chlorpheniramine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[79]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Methylscopolamine.	Peptic ulcer [DA61]	[60]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Chlorpheniramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[80]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[60]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Quetiapine.	Schizophrenia [6A20]	[60]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Aripiprazole.	Schizophrenia [6A20]	[60]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Iloperidone.	Schizophrenia [6A20]	[60]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Paliperidone.	Schizophrenia [6A20]	[60]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Molindone.	Schizophrenia [6A20]	[60]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Thiothixene.	Schizophrenia [6A20]	[60]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Chlorpheniramine and Asenapine.	Schizophrenia [6A20]	[60]
-----------


⏷ Show the Full List of 42 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
methylparaben	E00149	7456	Antimicrobial preservative
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Ethanethiol	E00116	6343	Flavoring agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Rosin	E00470	5280656	Binding agent; Film/membrane-forming agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 27 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlorpheniramine 12 mg tablet	12 mg	12 HR Extended Release Oral Tablet	Oral
Chlorpheniramine 4 mg tablet	4 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6976).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070797.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
7	Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol. 1999 Sep-Oct;13(5):391-9.
8	Inhibition by histamine H1 receptor antagonists of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes. Eur J Pharmacol. 1994 Jan 1;266(1):99-102.
9	Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24.
10	Drug Interactions Flockhart Table
11	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
30	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
31	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
32	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
33	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
34	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
35	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
36	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
37	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
38	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
39	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
40	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
41	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
42	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
43	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
44	Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
45	Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
46	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
47	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
48	Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
49	Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
50	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
51	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
52	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
53	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
54	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
55	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
56	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
57	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
58	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
59	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
60	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
61	Multum Information Services, Inc. Expert Review Panel.
62	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
63	Canadian Pharmacists Association.
64	Cerner Multum, Inc. "Australian Product Information.".
65	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
66	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
67	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
68	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
69	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
71	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
72	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
73	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
74	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
75	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
76	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
77	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
78	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
79	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
80	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.